Cystic Fibrosis
Patent oppositions filed in

Tezacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector used in the treatment of Cystic Fibrosis (CF). It is used in combination with Ivacaftor as Symdeko and in a triple combination regime along with drugs Elexacaftor and Ivcaftor as Trikafta for management of CF.

This drug is missing the following documents, can you help us by contributing something?


Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
India25-03-2021Dr.Charanjith Kumar SehgalPre-GrantOpponent did not attend the hearing, the application is rejectedCompositions3140/KOLNP/2012View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top

Patent Office Decisions

This table showcases the final ruling of patent offices over cases where patents have been opposed.

To better identify the case, the number of the patent application is provided in the table below.

Decision typeCountryDatePatent officeRelated patent applicationMore info
RejectionIndia12-12-2022Indian Patent Office3140/KOLNP/2012View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top